Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Patent
1992-11-06
1995-01-24
Hollinden, Gary E.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
3246531, 3246534, 436173, 514 54, 514 60, 423632, 423633, A61B 5055
Patent
active
053841093
DESCRIPTION:
BRIEF SUMMARY
This invention relates to the use of paramagnetic and superparamagnetic substances as enhancing agents for diagnostic magnetometery, especially using a superconducting quantum interference device magnetometer (a SQUID) and preferably as imaging contrast agents in magnetometric imaging, in particular SQUID imaging.
In 1963 James Zimmerman, a researcher at Ford Motor Company, observed that when a non-superconducting boundary is present in a superconducting loop a special effect is created. This effect is extremely sensitive to magnetic flux and based on Zimmerman's work the very highly sensitive SQUID magnetometers have been developed and are now available commercially from companies such as Biomagnetic Technologies Inc of San Diego, Calif. and Siemens AG of West Germany.
SQUID magnetometers generally comprise a superconducting pick up coil system and a detector system (the SQUID) which itself comprises one or two Josephson junctions inserted into a loop of superconducting wire. The magnetic flux within such loops is quantized and changes in the magnetic field experienced by the pick up coils cause an immediate and measurable change in the current flowing through the detector. The SQUID magnetometers available include both single and multichannel devices, the latter being capable of detecting magnetic fields at plurality of locations simultaneously.
SQUID magnetometers are capable of measuring magnetic fields as low as 10.sup.-14 Tesla, one ten billionth the earth's magnetic field, and thus are able to detect magnetic fields generated by biological activity such as for example the fields of the order of 10.sup.-13 T which are induced by the electrical activity of the brain. The sources of nerve signals can thus be traced to within a few millimeters.
SQUIDS and their use in the study of biomagnetism are discussed for example by Wolsky et al. Scientific American, February 1989, pages 60-69, Philo et al. Rev. Sci. Instrum. 48:1529-1536 (1977), Cohen IEEE Trans. Mag. MAG-11(2):694-700 (1975), Farrell et al. Applied Physics Communications 1(1):1-7 (1981), Farrell et al. IEEE Trans. Mag. 16:818-823 (1980), and Brittenham et al. N. Eng. J. Med. 307(27):1671-1675 (1982). The SQUID may be designed to detect the magnetic field or, may be of the gradiometer type and which several designs exist.
Indeed the development of biomagnetic analysis has been closely linked to the development of SQUID detectors since conventional magnetometers, such as Bartington detectors or Hall-probe gaussmeters, are several orders of magnitude less sensitive to magnetic field changes.
In the study of biomagnetism, or more specifically, the in vive measurement of magnetic susceptibility, the sensitivity of SQUIDS has been such that the researchers' concentration has primarily been on three areas--the detection of electrical activity within body tissues by detection of the accompanying magnetic field changes, the in vive determination of iron concentrations in the liver in order to detect iron overload or iron deficiency there, and the detection of ferromagnetic particle contamination in the lungs.
In the first two cases, the magnetic fields detected by the SQUIDS arise from normal or stimulated nerve activity or from the normal presence of (paramagnetic) iron in the liver. In the third case, particle contamination is by magnetic particles, e.g. of magnetite, and their magnetic effect is first maximized by placing the subject in a magnetic field. The resultant magnetization is detectable by a SQUID for the period of months over which it decays.
Due to the extreme sensitivity of the SQUID technology enabling the body's electrical activity to be monitored, there has been little emphasis on the use of SQUIDS for the generation of images, in particular two or three dimensional images, of the body's internal physical structure rather than electrical activity images.
For such localisation to be effective it must be possible to generate magnetic susceptibility differences between different body tissues, organs and ducts and rather than doing this by
REFERENCES:
patent: 4735796 (1988-04-01), Gordon
patent: 4813399 (1989-03-01), Gordon
patent: 4827945 (1989-05-01), Groman et al.
patent: 4996991 (1991-03-01), Gordon
Colfield et al., Chemical Abstracts, 104:217805s (1986).
Day et al., Biophys. J., 52, Nov. 1987, pp. 837-853.
Sundfors et al., J. de Phys., Coll. C10, 46:C10.785 (1985).
Mateew, Solid State Communications, 31, pp. 1009-1010 (1979).
Swithenby, Phys. Technol., 18, pp. 17-24 (1987).
Farrell et al., Biomagnetism, Walter de Gruyter, Berlin 1981, pp. 507-518.
Rassi et al., 7th Int. Conf. on Biomagnetism, New York (Aug. 1990), pp. 261-262.
Fischer et al., 7th Int. Conf. on Biomagnetism, New York (Aug. 1990), pp. 285-286.
Farrell et al., IEEE Transactions on Magnetics, MAG-16, 5 pp. 818-823 (1980).
Cohen, IEEE Trasactions on Magnetics, MAG-11, 2, pp. 694-700 (1975).
Ege Thorfinn
Klaveness Jo
Rocklage Scott M.
Hollinden Gary E.
Nycomed Imaging AS
LandOfFree
Diagnostic magnetometry using superparamagnetic particles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic magnetometry using superparamagnetic particles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic magnetometry using superparamagnetic particles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1467176